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Abstract: Endothelial dysfunction is the initial pathophysiological step in a progression of 
vascular damage that leads to overt cardiovascular and chronic kidney disease. Angiotensin 
II, the primary agent of the renin–angiotensin system (RAS), has a central role in endothelial 
dysfunction. Therefore, RAS blockade with an angiotensin receptor blocker (ARB) and/or 
angiotensin-converting enzyme (ACE) inhibitor provides a rational approach to reverse 
endothelial dysfunction, reduce microalbuminuria, and, thus, improves cardiovascular and renal 
prognosis. ARBs and ACE inhibitors act at different points in the RAS pathway and recent 
evidence suggests that there are differences regarding their effects on endothelial dysfunction. In 
addition to blood pressure lowering, studies have shown that ARBs reduce target-organ damage, 
including improvements in endothelial dysfunction, arterial stiffness, the progression of renal 
dysfunction in patients with type 2 diabetes, proteinuria, and left ventricular hypertrophy. The 
ONgoing Telmisartan Alone in combination with Ramipril Global Endpoint Trial (ONTARGET) 
Programme is expected to provide the ultimate evidence of whether improved endothelial func-
tion translates into reduced cardiovascular and renal events in high-risk patients, and to assess 
possible differential outcomes with telmisartan, the ACE inhibitor ramipril, or a combination 
of both (dual RAS blockade). Completion of ONTARGET is expected in 2008.
Keywords: angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, endothelial 
dysfunction, ONTARGET, renin–angiotensin system, telmisartan
Introduction
Cardiovascular disease is the leading cause of morbidity and mortality worldwide, 
resulting in an estimated 17 million deaths each year, particularly from myocardial 
infarction and stroke (Ezzati et al 2003). The number of patients with renal disease 
who require dialysis is also currently high and is expected to double to 2 million by 
2010 (Perico et al 2005). Endothelial dysfunction is the initial pathophysiologic step 
in the cardiovascular–renal continuum, which is a progression of vascular damage 
that is triggered by risk factors such as hypertension and leads to both kidney failure 
and overt cardiovascular disease (Brunner et al 2005). Prospective studies have dem-
onstrated that, in the peripheral and coronary circulation, endothelial dysfunction is 
highly predictive of future cardiovascular morbidity (Schachinger et al 2000; Heitzer 
et al 2001; Perticone et al 2001). Therefore, it has been hypothesized that treatment 
to reverse endothelial dysfunction may lead to a reduction in cardiovascular and renal 
events.
Blockade of the renin–angiotensin system (RAS) with angiotensin receptor block-
ers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors has been shown to 
provide improved endothelial function in patients with type 2 diabetes and nephropathy Vascular Health and Risk Management 2007:3(1)  2
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(Karalliedde and Viberti 2006). These agents also reduce 
microalbuminuria, a marker of increased permeability due to 
endothelial dysfunction. Recent evidence suggests that there 
is no clear-cut difference between ARB and ACE inhibitor 
agents in their effects on endothelial dysfunction and low-
grade albuminuria (Schmieder et al 2005). Signiﬁcant pro-
spective data are essential to investigate whether improved 
endothelial function translates into reduced cardiovascular 
and renal events in high-risk patients, and to assess pos-
sible differential outcomes with ARBs, ACE inhibitors, or 
a combination of both (dual RAS blockade). The ONgoing 
Telmisartan Alone in combination with Ramipril Global 
Endpoint Trial (ONTARGET) Programme is expected to 
provide ultimate evidence of the risk reduction that can be 
achieved with these treatments.
This review will discuss the pathophysiology of 
endothelial dysfunction, its role in the cardiovascular–renal 
continuum, and the potential for improvements with RAS 
blockers. The expectations and possible clinical implica-
tions of the wealth of data due from ONTARGET will be 
considered.
Pathophysiology of endothelial 
dysfunction and its role in the 
cardiovascular–renal continuum
The endothelium is a major regulator of vascular homeostasis, 
and its functional integrity is essential for the maintenance of 
blood ﬂow and antithrombotic activity (Brunner et al 2005; 
Deanﬁeld et al 2005). Endothelial cells, a monolayer between 
circulating blood and vascular smooth muscle, produce sig-
naling molecules that modulate tone, monocyte adhesion, 
and platelet–neutrophil aggregation in the vascular smooth 
muscle cells. The balance between the actions of these sig-
naling molecules is of critical importance. One important 
signaling molecule released by vascular endothelial cells is 
nitric oxide (NO), formed from L-arginine in the presence of 
NO synthase (Palmer et al 1988). NO is both a potent vaso-
dilator and an inhibitor of platelet adhesion and aggregation, 
and exerts antiﬁbrotic effects. 
Endothelial dysfunction can be deﬁned as an imbalance 
between vasodilating and vasoconstricting substances pro-
duced by (or acting on) endothelial cells (Brunner et al 2005). 
In particular, the dysfunctional endothelium is characterized 
by impaired NO synthesis or increased NO degradation. 
Potentially harmful effects include vasoconstriction, platelet 
aggregation, white blood cell adhesion, and proliferation of 
smooth muscle cells (Anggard 1994; Klahr 2001). The result 
is a reduction of regional or whole-organ perfusion, leading to 
target-organ damage and an increased incidence of ischemic 
events (Schachinger et al 2000; Heitzer et al 2001; Perticone 
et al 2001). Thus, endothelial dysfunction is an early marker 
of vascular disease, and leads to both cardiovascular and renal 
morbidity (Panza et al 1990; McAllister et al 1999; Raptis 
and Viberti 2001; Taylor 2001; Annuk et al 2003). 
Endothelial dysfunction can be assessed by biochemical 
markers, molecular genetic tests and invasive or non-invasive 
techniques, although the optimal methodology is still unclear 
(Deanﬁeld et al 2005; Lee et al 2006). Current biochemical 
markers include, for example, adhesion molecules ICAM-2, 
VCAM-1, E-selectin, P-selectin and sCD40L, cytokines 
interleukin 6, interleukin 18, hs-CRP and ET-1 (Deanﬁeld 
et al 2005). Genetic markers include von Willebrand factor 
(vWF), angiotensin I converting enzyme (ACE), preproen-
dothelin (ET)-1, endothelin I converting enzyme (ECE-1), 
endothelin B receptor, eNOS, NF-κB, ICAM-1, VCAM-1, 
and E-selectin (Deanﬁeld et al 2005). 
Non-invasive techniques include ﬂow-mediated vasodila-
tion (FMD) in the brachial or radial artery (Celermajer et al 
1992). Invasive procedures are forearm blood ﬂow (FBF) by 
cannulation of the brachial artery (Panza et al 1990) or for 
coronary circulation, an infusion of intracoronary acetylcho-
line (ACh) (Hasdai and Lerman 1999).
Recent evidence conﬁrms that there is a close link 
between cardiovascular and renal changes, and that they 
are triggered by similar risk factors, such as hypertension, 
hyperglycemia, dyslipidemia, and obesity (Figure 1) 
(Hillege et al 2002; Anavekar et al 2004; Stam et al 2006). 
Mechanical and chemical damage resulting from these 
interrelated risk factors promote a general progression of 
vascular damage that begins with endothelial dysfunc-
tion and atherosclerosis, which leads to proteinuria, left 
ventricular hypertrophy, and transient ischemic attacks in 
the brain, then progresses to chronic kidney disease, overt 
cardiovascular disease, and stroke (Brunner et al 2005). This 
is known as the cardiovascular–renal continuum (Figure 1). 
It is now understood that cardiovascular prognosis is clearly 
reﬂected by measures of renal dysfunction, such as increased 
albuminuria and a decline in the glomerular ﬁltration rate 
(GFR), with even modest changes markedly increasing 
the risk for cardiovascular disease (Gerstein et al 2001; 
Hillege et al 2002; Anavekar et al 2004; Arnlov et al 2005). 
Thus, renal dysfunction is a risk factor for cardiovascular 
death. In fact, most patients with renal impairment die from Vascular Health and Risk Management 2007:3(1)  3
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cardiovascular causes, rather than from end-stage renal 
disease (Gerstein et al 2001; Hillege et al 2002; Anavekar 
et al 2004). 
Microalbuminuria occurs early in the cardiovascular–renal 
continuum, closely following endothelial dysfunction (Figure 1) 
(de Jong and de Zeeuw 2005). These small losses of protein 
in the urine develop when the loss of endothelial integrity 
in the kidney results in intraglomerular hypertension and 
inﬂammation (Klahr and Morrissey 2000). Microalbuminuria 
is frequently detected in individuals with atherosclerosis and 
has been found to be a risk factor for type 2 diabetes and car-
diovascular disease (Gerstein et al 2001; Hillege et al 2002; 
Anavekar et al 2004; Arnlov et al 2005; Brantsma et al 2005). 
Thus, microalbuminuria is an early marker of widespread 
vascular, renal, and other target-organ damage.
The physiological actions of angiotensin II in cardio-
vascular, renal, neuronal, endocrine and hepatic systems 
are nearly all mediated by the angiotensin II receptor. 
Actions include, for example, the regulation of arterial 
blood pressure, electrolyte and water balance, and renal 
function (de Gasparo et al 2000). Angiotensin II is a potent 
arteriole vasoconstrictor which can increase total periph-
eral resistance thereby increasing arterial pressure. As the 
primary agent of the RAS, angiotensin II also has a central 
role in endothelial dysfunction (Figure 2) (Dzau 2001). In 
addition to increasing blood pressure, angiotensin II acts via 
the angiotensin II type 1 receptor (AT1) receptor to increase 
oxidative stress, causing NO breakdown (de Gasparo 2002; 
Zhou et al 2004). Elevated levels of Angiotensin II in the 
endothelium stimulates nicotinamide adenine dinucleotide 
phosphate (NADPH) and nicotinamide adenine dinucleotide 
(NADH) oxidase to generate reactive oxygen species (ROS) 
responsible for NO breakdown (Griendling et al 1994). This 
leads to endothelial dysfunction, cell growth, inﬂammation 
by the activation of nuclear factor-κB (NF-κB), monocyte 
chemoattractant protein-1 (MCP-1), vascular cell adhesion 
molecule (VCAM), and the release of the cytokines interleu-
kin-6 (IL-6) and tumor necrosis factor-α (TNF-α) (Marui et 
al 1993; Hernandez-Presa et al 1997; Han et al 1999). VCAM 
and cytokine action increases the adhesiveness of the endo-
thelium and subsequently the binding of inﬂammatory cells 
to the endothelial surface leading to vascular inﬂammation 
and thrombosis (Figure 3) (Kranzhöfer et al 1999; Schmieder 
2005). Thus, angiotensin II is involved in every step of the 
cardiovascular–renal continuum, promoting a wide variety 
of deleterious effects on target organs. 
RAS blockade to reverse 
endothelial dysfunction
In addition to blood pressure-lowering effects, RAS blockade 
with an ARB and/or ACE inhibitor provides a rational 
approach to reversing endothelial dysfunction by reducing 
the harmful effects of angiotensin II (Karalliedde and Viberti 
2006). Such treatments may provide cardiovascular and renal 
protection beyond that of reducing a single cardiovascular 
risk factor. Indeed, current clinical guidelines recommend 
ARBs as ﬁrst-line treatment in patients with type 2 diabetes 
and nephropathy (American Disease Association 2004). 
ARBs and ACE inhibitors act at different points in the RAS 
pathway (Figure 2). ACE inhibitors prevent the generation 
Figure 1 The cardiovascular–renal continuum. Vascular Health and Risk Management 2007:3(1)  4
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of angiotensin II, which subsequently can activate both AT1 
and angiotensin II type 2 (AT2) receptors (Burnier 2001). 
ACE inhibitors also inhibit the breakdown of bradykinin 
by kinase II, thereby increasing bradykinin levels. This 
may cause vasodilation, thereby decreasing blood pressure, 
and may improve endothelial function (Chen et al 2003). 
However, bradykinin and the structurally related substance 
P can also potentially cause cough, a side effect that many 
patients ﬁnd unacceptable (Chen et al 2003). In addition, 
ACE inhibitors can allow continued activation of AT1 by 
angiotensin II via alternative pathways, a phenomenon 
known as “angiotensin II escape” (Roig et al 2000). Dur-
ing long-term therapy, angiotensin II concentrations can 
revert to pretreatment levels, thus attenuating the protective 
effect of ACE inhibition. Angiotensin II escape may be a 
particular problem for the local kidney RAS, in which up 
to 40% of angiotensin II formation is via non-ACE path-
ways (Hollenberg et al 1998). This may explain why ACE 
inhibitors do not reduce levels of angiotensin II in the renal 
interstitial ﬂuid (Nishiyama et al 2002). ACE inhibitors and 
vascular diseases has recently been reviewed by Napoli and 
Loscalzo (2005).
In contrast to ACE inhibitors, ARBs are highly selective 
for the AT1 receptor, which is believed to be responsible 
for the pathophysiologic effects of angiotensin II (Burnier 
et al 2001). The AT2 receptor generally has effects opposed 
to those of AT1 and is abundantly expressed in endothelial cells 
(Ardaillou 1999) (Figure 2). ARBs do not increase bradykinin 
levels and are, therefore, not associated with cough. Further-
more, ARBs maintain selective blockade of AT1 and are, 
thus, not associated with angiotensin II escape. 
Telmisartan is a potent selective once-daily ARB that 
provides a sustained blood pressure-lowering effect over 
24 hours (Battershill and Scott 2006). As discussed below, 
studies have shown that telmisartan also reduces target-organ 
damage, including improvements in endothelial dysfunction 
(Svolis et al 2002; Schmieder et al 2005; Symeonides et al 
2006), arterial stiffness (Asmar et al 2002; Uchida et al 2004), 
the progression of renal dysfunction in patients with type 2 
diabetes (Barnett et al 2004), proteinuria (Redón et al 2005; 
Ryšavá et al 2005; Sengul et al 2006), and left ventricular 
hypertrophy (Galzerano et al 2004; Ivanova et al 2005). In 
clinical trials, other ARBs have also demonstrated effective 
renoprotection in patients with type 2 diabetes and renal dis-
ease (Brenner et al 2001; Lewis et al 2001; Parving et al 2001; 
Viberti and Wheeldon 2002; Klingbeil et al 2003). These trials 
showed that ARBs can reverse microalbuminuria, suppress 
the progression of albuminuria and loss of renal function, 
and prevent progression to end-stage renal disease. 
RAS blockade with ACE inhibitors may demonstrate 
favorable effects on the endothelium. In short-term clinical 
studies, ACE inhibitors reduced microalbuminuria and, in 
the longer term, they are superior to non-RAS-targeting 
antihypertensive agents in maintaining normal renal function 
(ACE inhibitors in diabetic nephropathy trialist group 2001). 
In one study, hypertensive patients receiving ACE inhibitors 
Figure 2 Blockade of the RAS pathway with ACE inhibitors and ARBs. Vascular Health and Risk Management 2007:3(1)  5
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displayed improved maximal forearm blood ﬂow response to 
hyperemia that was signiﬁcantly greater (p < 0.05) than the 
response in patients treated with calcium channel blockers, 
β-blockers, or diuretics (Higashi et al 2000).
Improved endothelial function 
with telmisartan
The Telmisartan versus Ramipril in renal ENdothelial DYs-
function (TRENDY) study showed that both telmisartan 
and ramipril improved endothelial function (increased NO 
activity) in patients with type 2 diabetes and hypertension 
(Schmieder et al 2005). TRENDY was the ﬁrst head-to-head 
comparison of the effect of an ARB versus an ACE inhibi-
tor on endothelial function. In a prospective, randomized, 
double-blind, forced-titration design, 96 patients with type 2 
diabetes, normoalbuminuria or microalbuminuria, thus early-
stage nephropathy, were randomized to 9 weeks’ treatment 
with telmisartan 40–80 mg or ramipril 5–10 mg, with add-on 
therapy (hydrochlorothiazide, metoprolol, or atenolol) to 
achieve blood pressure control. The primary end point was 
renal plasma ﬂow in response to N-monomethyl-L-arginine 
(L-NMMA) infusion. Telmisartan signiﬁcantly increased 
the response of renal plasma ﬂow to L-NMMA infusion 
(p < 0.001 vs baseline) taken as an indicator of NO activity 
(Figure 4) (Schmieder et al 2005). At rest (ie, without the 
stimulus), telmisartan also signiﬁcantly improved (p < 0.05) 
renal plasma ﬂow (by 27.3 mL/min) and reduced renal 
vascular resistance (by 7%). In addition, although levels of 
albuminuria were low at baseline, telmisartan signiﬁcantly 
improved (p < 0.05) albuminuria (reduced from 9.0 to 
7.2 mg/24 hours). Ramipril also increased the response of 
renal plasma ﬂow to L-NMMA infusion (p < 0.02 versus 
baseline) but, in contrast to telmisartan, the ACE inhibitor 
ramipril did not improve renal plasma ﬂow or reduced renal 
vascular resistance signiﬁcantly. 
In a 3-month, double blind, cross-over study, endothelial 
function was improved by telmisartan 40 mg but to a lower 
extent by ramipril 2.5 mg in 40 non-hypertensive patients with 
controlled type 2 diabetes without coronary artery disease, left 
ventricular dysfunction, or microalbuminuria (Symeonides 
et al 2006). Brachial artery ﬂow-mediated dilation was 
improved 96% by telmisartan compared with only 36% by 
ramipril. Interestingly, the combination of telmisartan and 
ramipril increased dilation by 111%. Tissue plasminogen 
activator and von Willebrand factor, measures of endothelial 
health and ﬁbrinolytic status, were improved in this study, with 
the combination of the ARB and the ACE inhibitor again pro-
ducing the greatest beneﬁt. Telmisartan has also been shown to 
improve endothelial function in treatment-naïve hypertensive 
patients with chronic heart failure (Svolis et al 2002). 
Figure 3 Schematic representation of the multiple effects of increased tissue production of angiotensin II. Reprinted from Schmieder RE, 2005. Mechanisms for the clinical 
beneﬁts of Angiotensin II receptor blockers. Am J Hypertens, 18:720–30. Copyright © 2005, with permission from American Journal of Hypertension, Ltd. 
Abbreviations: ET-1, endothelin-1; MCP-1, monocyte chemoattractant protein-I; MMP, matrix metalloproteinase; NF-kB, nuclear factor-kB; NO, nitric oxide; PAI-1,  
plasminogen activator type 1; VCAM, vascular cell adhesion molecule; ACE, angiotensin-converting enzyme.Vascular Health and Risk Management 2007:3(1)  6
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Decline in GFR is an important sign of renal damage. The 
Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) 
study showed that both telmisartan and the ACE inhibitor 
enalapril similarly reduced the decline in GFR over 5 years 
in patients with hypertension and early type 2 diabetic 
nephropathy (Barnett et al 2004). In a prospective, random-
ized, double-blind, forced-titration design, 250 patients were 
randomized to telmisartan 40–80 mg or enalapril 10–20 mg, 
each with add-on therapy to control blood pressure. After 
the ﬁrst year, both treatments reduced GFR decline with a 
consistent, year-on-year effect. By year 3, the annual decline 
in GFR stabilized to approximately 2 mL/min/1.73 m2. This 
is substantially lower than the annual decline of 10–12 mL/
min/1.73 m2 that is observed in untreated diabetic patients 
with proteinuria (Barnett 2005). There were no signiﬁcant 
differences in blood pressure lowering between the groups.
Clinical studies have consistently shown that telmisartan 
reduces proteinuria (Redón et al 2005; Ryšavá et al 2005; 
Sengul et al 2006). A 12-month study of 206 patients 
assessed the interactions between RAS gene polymorphisms 
and telmisartan therapy in patients with mild-to-moderate 
hypertension (Redón et al 2005). Microalbuminuria was 
present in 28% of patients, and mean urinary albumin excre-
tion was 32.7 mg/day. Telmisartan treatment signiﬁcantly 
reduced albuminuria by 69% by month 12. The effects of 
3 months’ treatment with telmisartan 40–80 mg/day were 
examined in 92 patients with hypertension (60 with diabetes), 
serum creatinine <350 µmol/L, and proteinuria >1 g/day 
(Ryšavá et al 2005). Telmisartan reduced proteinuria by 
21%; corresponding to a decrease of 0.76 g/24 hours from 
3.62 g/24 hours.
Telmisartan, when given in addition to the ACE inhibi-
tor lisinopril, provided further reductions in the albumin 
excretion compared with ACE inhibitor monotherapy 
(Sengul et al 2006). Patients with type 2 diabetes and micro-
albuminuria (n = 219) had been receiving ACE inhibitors for 
at least 6 months previously, then received either telmisartan 
80 mg or lisinopril 20 mg monotherapy for a further 6 months. 
Half of the patients then received combination therapy with 
telmisartan 80 mg/lisinopril 20 mg. At 6 months, reduc-
tions in albuminuria were 31% with telmisartan and 37% 
with lisinopril. After 12 months, telmisartan had reduced 
albuminuria by an additional 30%. Similar results were seen 
in the group in which lisinopril was added to telmisartan. 
Both treatments produced comparable reductions in blood 
pressure, supporting the notion that the further reduction of 
proteinuria was blood pressure independent.
Arterial stiffness is an early sign of atherosclerosis and 
an important risk factor for cardiovascular disease (Safar 
et al 2003). In one study of arterial stiffness, 24 patients 
with hypertension received telmisartan 40 mg for 3 months 
(Uchida et al 2004). Brachial-ankle pulse wave velocity was 
reduced by 12% from 18.92 m/s at baseline to 16.72 m/s 
(p < 0.01). The improvement in pulse wave velocity was 
greater than predicted on the basis of the reduction in blood 
pressure observed. In another study, telmisartan signiﬁcantly 
reduced arterial stiffness, measured by carotid-femoral pulse 
wave velocity, compared with placebo in 28 patients with 
type 2 diabetes and hypertension (Asmar et al 2002). 
The ONTARGET trial
The ONTARGET Trial Programme is comparing telmisartan, 
ramipril, and the combination of both antihypertensive agents 
in the prevention of cardiovascular morbidity and mortality 
in patients at high risk (Teo et al 2004). Telmisartan was 
the ARB selected for The ONTARGET Trial Programme 
because it provides sustained antihypertensive activity 
effect over the 24-hour period between doses (Battershill and 
Scott 2006). The comparator, the ACE inhibitor ramipril, was 
selected because in the Heart Outcomes Protection Evalua-
tion (HOPE) trial, it was proven to reduce the incidence of 
cardiovascular events in a similar patient population (55 years 
of age or older, with evidence of vascular disease or diabetes 
plus one other cardiovascular risk factor and who were not 
known to have a low ejection fraction or heart failure) (Yusuf 
et al 2000). Patients enrolled in ONTARGET have vascular 
disease (coronary artery disease, peripheral arterial occlusive 
disease, or stroke), or diabetes with end-organ damage (Teo 
Figure 4 Improved endothelial function with telmisartan compared with ramipril 
in the TRENDY study. From Schmieder et al. 2005. Effects of telmisartan versus 
ramipril on endothelium function of the renal vasculature in type 2 diabetes. 
J Hypertens, 23:S147.Vascular Health and Risk Management 2007:3(1)  7
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et al 2004). The primary outcome is a composite end point 
of cardiovascular death, stroke, acute myocardial infarction, 
and hospitalization for chronic heart failure. A variety of renal 
end points have also been included. Telmisartan Randomized 
AssessmeNt Study in ACE-I-iNtolerant subjects with cardio-
vascular Disease (TRANSCEND) is a parallel study within 
The ONTARGET Trial Programme that is comparing the 
cardiovascular protective effect of telmisartan with placebo 
in patients intolerant to ACE inhibitors (Teo et al 2004).
ONTARGET has several important features. The trial 
has recruited 25620 patients from 800 centers in 40 countries 
throughout Europe, North America, Africa, Australasia, and 
Asia (Teo et al 2004), and ﬁndings will be based on more 
than 100 000 patient-years of data. This makes ONTARGET 
the largest ever randomized clinical trial to test the effects 
of an ARB versus an ACE inhibitor and of combination 
treatment of an ARB with an ACE inhibitor on cardio-
vascular risk reduction. Results from previous trials (see 
above) suggested that treatment with telmisartan or ramipril 
reduces the cardiovascular outcome to similar extent, with 
the combination to be superior. Thus, ONTARGET should 
provide the ultimate evidence regarding the cardiovascular 
beneﬁt of different strategies to block the RAS in high-risk 
patients. Furthermore, TRANSCEND, which has enrolled 
5926 patients, is the largest trial to evaluate the cardiovas-
cular protective effects of telmisartan in patients with ACE 
inhibitor intolerance.
Baseline characteristics are now available for all patients 
recruited into the ONTARGET study (Safar et al 2003). 
Importantly, patients have controlled hypertension (mean 
blood pressure at randomization was 134/77 mm Hg) and 
cardiovascular risk factors at baseline, and are thus repre-
sentative of those seen in everyday clinical practice. Com-
pared with the HOPE study, patients in ONTARGET have 
greater ethnic diversity, are slightly older, are more likely 
to have cerebrovascular disease and hypertension, and have 
increased statin use (60.7% and 28.9%, respectively). These 
differences reﬂect the changing approach to cardiovascular 
disease prevention. 
The ONTARGET Trial Programme is the ﬁrst long-term 
prospective trial to investigate the efﬁcacy of an ARB/ACE 
inhibitor combination (dual RAS blockade). Due to the 
different mechanisms of action of telmisartan and ramipril, 
there is the potential for differential cardiovascular outcomes, 
independent of their effects on blood pressure. The combi-
nation may be able to fully suppress the deleterious effects 
of angiotensin II and, at the same time, provide additive 
improvements in renal bradykinin and cyclic guanosine 
monophosphate, two molecules that improve endothelial 
function (Siragy et al 2001). Therefore, the combination may 
offer superior cardiovascular protection compared with either 
monotherapy as a result of their complementary effects. 
Predeﬁned substudies should provide greater under-
standing of differences in the cardiovascular risk reduction 
achieved by RAS blockade with telmisartan, ramipril, and 
the combination (Safar et al 2003). The incidence and time 
course of erectile dysfunction is being evaluated during 
drug treatment in 1500 patients from both ONTARGET and 
TRANSCEND. Previous studies have shown that erectile 
dysfunction is caused by premature atherosclerosis and such 
antihypertensive drugs as β-blockers and diuretics (Brunner 
et al 2005). Therefore, the choice of antihypertensive medi-
cation appears to be critical. Furthermore, drugs known to 
improve or delay endothelial dysfunction may have a positive 
impact on erectile dysfunction. The substudy of ONTARGET/
TRANSCEND will assess whether erectile dysfunction is 
related to cardiovascular risk factors and to the use of car-
dioprotective drugs. The primary end point is the onset of 
change of erectile dysfunction, assessed using the modiﬁed 
“Cologne Male Survey” questionnaire, in patients receiving 
placebo, telmisartan, ramipril, or both active agents.
In another substudy, 284 patients enrolled in TRANSCEND 
will undergo evaluation of arterial stiffness. As mentioned 
above, telmisartan has proven beneﬁts on arterial stiffness in 
patients with type 2 diabetes and hypertension (Asmar et al 
2002; Uchida et al 2004). The arterial stiffness substudy of 
TRANSCEND will answer the question of whether changes 
in arterial stiffness correlate with clinical outcome. The 
primary end point is change in aortic stiffness determined 
by carotid-femoral pulse wave velocity. As a secondary end 
point, the predictive value of early, short-term changes in 
arterial stiffness on the long-term clinical outcome of patients 
is being evaluated. 
Conclusions
The ONTARGET Trial Programme is due to be completed 
in 2008, and results are expected to provide clinicians with 
a wealth of data to improve evidence-based treatment of 
patients at high risk of cardiovascular events. By blocking the 
RAS, ACE inhibitor and ARB treatment may, in addition to 
blood-pressure lowering, have positive effects on endothelial 
function, the initial step in vascular damage. This should pro-
vide greater beneﬁts than treating individual cardiovascular 
risk factors. With over 100000 patient-years of data, the pro-Vascular Health and Risk Management 2007:3(1)  8
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gram is expected to provide the ultimate evidence for whether 
improved endothelial function does indeed translate into 
reduced cardiovascular and renal events in high-risk patients. 
In addition, the trial will establish whether treatment with 
the ARB telmisartan, the ACE inhibitor ramipril, and dual 
RAS blockade with both agents is associated with differential 
cardiovascular/renal outcomes. Due to its high selectivity for 
the AT1 receptor, telmisartan may prove to exert excellent 
cardiovascular protection. The complementary mechanisms 
of action of telmisartan and ramipril may lead to superior 
cardiovascular protection with the combination compared 
with either monotherapy. Thus, the ONTARGET data are 
expected to have a substantial impact on clinical practice by 
allowing physicians to choose the optimal treatment regimen 
to protect their patients at risk of future cardiovascular or 
renal morbidity and mortality.
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